Skip to main content
Have a personal or library account? Click to login
Post‑Measles Complications and Mortality in Children under Five Years in Low‑ and Middle‑Income Countries: A Narrative Review Cover

Post‑Measles Complications and Mortality in Children under Five Years in Low‑ and Middle‑Income Countries: A Narrative Review

Open Access
|Oct 2026

References

  1. World Health Organization. Measles deaths down 88% since 2000, but cases surge. Who.int. Published November 28, 2025. https://www.who.int/news/item/28-11-2025-measles-deaths-down-88--since-2000--but-cases-surge.
  2. Gavi, the Vaccine Alliance. Measles vaccines have contributed to dramatic reduction in cases and deaths since 2000. Gavi.org. Published November 27, 2025. https://www.gavi.org/news/media-room/measles-vaccines-have-contributed-dramatic-reduction-cases-and-deaths-2000.
  3. World Health Organization. Progress towards measles elimination. WHO.int. Published 2026. https://iris.who.int/bitstreams/8ac932cb-6d3f-4922-8335-f34d70419fe3/download.
  4. Tran ICT, Gregory CJ, O’Connor P, Imohe A, Ha LA, Suchdev PS. A scoping review on the associations and potential pathways between malnutrition and measles. medRxiv. Published January 23, 2023. doi:10.1101/2023.01.21.23284872.
  5. United Nations Children’s Fund, World Health Organization, World Bank Group. Levels and trends in child malnutrition: UNICEF/WHO/World Bank Group joint child malnutrition estimates: Key findings of the 2025 edition. World Health Organization; 2025. https://www.who.int/publications/i/item/9789240112308.
  6. Gignoux E, Polonsky J, Ciglenecki I, et al. Risk factors for measles mortality and the importance of decentralized case management during an unusually large measles epidemic in eastern Democratic Republic of Congo in 2013. PLoS One. 2018;13(3):e0194276. doi:10.1371/journal.pone.0194276.
  7. Global Humanitarian Overview 2026. Humanitarian Action. Humanitarianaction.info. Published December 8, 2025. https://humanitarianaction.info/document/global-humanitarian-overview-2026.
  8. UNICEF. How dangerous is measles? Unicef.org. Published 2024. https://www.unicef.org/eca/stories/how-dangerous-measles.
  9. Sbarra AN, Mosser JF, Jit M, et al. Estimating national‑level measles case–fatality ratios in low‑income and middle‑income countries: An updated systematic review and modelling study. Lancet Glob Health. 2023;11(4):e516–e524. doi:10.1016/S2214-109X(23)00043-8.
  10. Severity of measles in malnutrition. Nutr Rev. 1982;40(7):203–205. doi:10.1111/j.1753-4887.1982.tb05310.x.
  11. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature. 2000;406(6798):893–897. doi:10.1038/35022579.
  12. Naniche D, Varior‑Krishnan G, Cervoni F, et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol. 1993;67(10):6025–6032. doi:10.1128/jvi.67.10.6025-6032.1993.
  13. Noyce RS, Bondre DG, Ha MN, et al. Tumor cell marker PVRL4 (Nectin 4) is an epithelial cell receptor for measles virus. PLoS Pathog. 2011;7(8):e1002240. doi:10.1371/journal.ppat.1002240.
  14. Strebel PM, Papania MJ, Gastañaduy PA, Goodson JL. Measles vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM. eds. Plotkin’s Vaccines. 7th ed. Elsevier; 2018:579–618.e21. doi:10.1016/b978-0-323-35761-6.00037-7.
  15. Sommer A. Vitamin A deficiency. Encyclopedia of Life Sciences. Published April 19, 2001. doi:10.1038/npg.els.0002106.
  16. World Health Organization. Global prevalence of vitamin A deficiency in populations at risk 1995–2005: WHO global database on vitamin A deficiency. https://www.who.int/publications/i/item/9789241598019.
  17. Patel MK. Progress toward regional measles elimination—worldwide, 2000–2018. MMWR Morb Mortal Wkly Rep. 2019;68(48). doi:10.15585/mmwr.mm6848a1.
  18. Kirolos A, Goyheneix M, Eliasz MK, et al. Neurodevelopmental, cognitive, behavioural and mental health impairments following childhood malnutrition: A systematic review. BMJ Glob Health. 2022;7(7):e009330. doi:10.1136/bmjgh-2022-009330.
  19. Guerrant RL, Oriá RB, Moore SR, Oriá MO, Lima AA. Malnutrition as an enteric infectious disease with long‑term effects on child development. Nutr Rev. 2008;66(9):487–505. doi:10.1111/j.1753-4887.2008.00082.x.
  20. Perry R. Measles. American Public Health Association eBooks; 2015. doi:10.2105/ccdm.2745.098.
  21. Fine P, Eames K, Heymann DL. “Herd immunity”: A rough guide. Clin Infect Dis. 2011;52(7):911–916. doi:10.1093/cid/cir007.
  22. Plans‑Rubió P. The vaccination coverage required to establish herd immunity against influenza viruses. Prev Med. 2012;55(1):72–77. doi:10.1016/j.ypmed.2012.02.015.
  23. World Health Organization. Global vaccine action plan 2011–2020. www.who.int. Published February 21, 2013. https://www.who.int/publications/i/item/global-vaccine-action-plan-2011-2020.
  24. Dabbagh A, Patel MK, Dumolard L, et al. Progress toward regional measles elimination—worldwide, 2000–2016. MMWR Morb Mortal Wkly Rep. 2017;66(42):1148–1153. doi:10.15585/mmwr.mm6642a6.
  25. Rey‑Benito G, Pastor D, Whittembury A, et al. Sustaining the elimination of measles, rubella and congenital rubella syndrome in the Americas, 2019–2023: From challenges to opportunities. Vaccines. 2024;12(6):690. doi:10.3390/vaccines12060690.
  26. Patel MK, Goodson JL, Alexander JP, et al. Progress toward regional measles elimination — worldwide, 2000–2019. MMWR Morb Mortal Wkly Rep. 2020;69(45):1700–1705. doi:10.15585/mmwr.mm6945a6.
  27. Utazi CE, Thorley J, Alegana VA, et al. Mapping vaccination coverage to explore the effects of delivery mechanisms and inform vaccination strategies. Nat Commun. 2019;10(1):1633. doi:10.1038/s41467-019-09611-1.
  28. Gans HA. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA. 1998;280(6):527. doi:10.1001/jama.280.6.527.
  29. Metcalf CJE, Bjørnstad ON, Grenfell BT, Andreasen V. Seasonality and comparative dynamics of six childhood infections in pre‑vaccination Copenhagen. Proc Biol Sci. 2009;276(1676):4111–4118. doi:10.1098/rspb.2009.1058.
  30. Bharti N, Tatem AJ, Ferrari MJ, Grais RF, Djibo A, Grenfell BT. Explaining seasonal fluctuations of measles in Niger using nighttime lights imagery. Science. 2011;334(6061):1424–1427. doi:10.1126/science.1210554.
  31. Paniz‑Mondolfi AE, Tami A, Grillet ME, et al. Resurgence of vaccine‑preventable diseases in Venezuela as a regional public health threat in the Americas. Emerg Infect Dis. 2019;25(4):625–632. doi:10.3201/eid2504.181305.
  32. Patel M, Lee AD, Redd SB, et al. Increase in measles cases—United States, January 1–April 26, 2019. MMWR Morb Mortal Wkly Rep. 2019;68(17):402–404. doi:10.15585/mmwr.mm6817e1.
  33. Gibson E, Durrheim DN, O’Connor P. Eliminating measles: Factors that contribute to re‑establishing transmission. Vaccines. 2025;13(11):1125. doi:10.3390/vaccines13111125.
  34. Hagan J, Dashpagma O, Vichit O, et al. Challenges for sustaining measles elimination: Post‑verification large‑scale import‑related measles outbreaks in Mongolia and Cambodia, resulting in the loss of measles elimination status. Vaccines. 2024;12(7):821. doi:10.3390/vaccines12070821.
  35. Takahashi S, Metcalf CJE, Ferrari MJ, Tatem AJ, Lessler J. The geography of measles vaccination in the African Great Lakes region. Nat Commun. 2017;8(1):15585. doi:10.1038/ncomms15585.
  36. Abbas M, Aloudat T, Bartolomei J, et al. Migrant and refugee populations: A public health and policy perspective on a continuing global crisis. Antimicrob Resist Infect Control. 2018;7(1). doi:10.1186/s13756-018-0403-4.
  37. Sodha SV, Dietz V. Strengthening routine immunization systems to improve global vaccination coverage. Br Med Bull. 2015;113(1):5–14. doi:10.1093/bmb/ldv001.
  38. Masresha BG, Wiysonge CS, Katsande R, O’Connor PM, Lebo E, Perry RT. Tracking measles and rubella elimination progress—World Health Organization African Region, 2022–2023. Vaccines. 2024;12(8):949. doi:10.3390/vaccines12080949.
  39. Mina MJ, Metcalf CJE, de Swart RL, Osterhaus ADME, Grenfell BT. Long‑term measles‑induced immunomodulation increases overall childhood infectious disease mortality. Science. 2015;348(6235):694–699. doi:10.1126/science.aaa3662.
  40. Petrova VN, Sawatsky B, Han AX, et al. Incomplete genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles. Sci Immunol. 2019;4(41):eaay6125. doi:10.1126/sciimmunol.aay6125.
  41. Ammar MA, Ali Khalil M, Essam Mohammed A. High measles complication rates and vaccine breakthroughs among pediatric cases in Iraq: A cross‑sectional study. F1000Res. 2026;15:151. doi:10.12688/f1000research.173528.1.
  42. Ilyas M, Afzal S, Ahmad J, Alghamdi S, Khurram M. The resurgence of measles infection and its associated complications in early childhood at a tertiary care hospital in Peshawar, Pakistan. Pol J Microbiol. 2020;69(2):177–184. doi:10.33073/pjm-2020-020.
  43. Tolera B, Fentie K, Lemessa S. Clinical characteristics and outcomes of children hospitalized with suspected measles at Jimma University Medical Center, Ethiopia, cross sectional study. Int J Clin Exp Med Sci. 2025;11(5):64–76. doi:10.11648/j.ijcems.20251105.12.
  44. Ali D, Detroz A, Gorur Y, Bosquee L, Villalba NL, Cardos B. Measles‑induced acute disseminated encephalomyelitis in a non‑vaccinated patient. Eur J Case Rep Intern Med. 2020;7(6):001332. doi:10.12890/2020_001332.
  45. Garg RK, Pandey S. Subacute sclerosing panencephalitis: Recent advances in pathogenesis, diagnosis, and treatment. Ann Indian Acad Neurol. 2025;28(2):159–168. doi:10.4103/aian.aian_1112_24.
  46. Sauter JJ. Xerophthalmia and measles in Kenya. 1976.
  47. Foster A, Sommer A. Corneal ulceration, measles, and childhood blindness in Tanzania. Br J Ophthalmol. 1987;71(5):331–343. doi:10.1136/bjo.71.5.331.
  48. Sandford‑Smith JH, Whittle HC. Corneal ulceration following measles in Nigerian children. Br J Ophthalmol. 1979;63(11):720–724. doi:10.1136/bjo.63.11.720.
  49. Animashaun A. Measles and blindness in Nigerian children. Niger J Paediatr. 2024;4(1):10–13. doi:10.47348/samlj/v36/i2a4. https://www.njpaediatrics.com/index.php/njp/article/view/1030.
  50. Masters NB, Beck AS, Mathis AD, et al. Measles virus transmission patterns and public health responses during Operation Allies Welcome: A descriptive epidemiological study. Lancet Public Health. 2023;8(8):e618–e628. doi:10.1016/s2468-2667(23)00130-5.
  51. Weida JA. Measles (rubeola). In: Kellerman RD, Rakel D, eds. Conn’s Current Therapy 2019. Elsevier; 2019:580–582.
  52. Orenstein WA, Hinman A, Nkowane B, Olive JM, Reingold A. Measles and rubella global strategic plan 2012–2020 midterm review. Vaccine. 2018;36:A1–A34. doi:10.1016/j.vaccine.2017.09.026.
  53. Moss WJ, Ota MO, Griffin DE. Measles: Immune suppression and immune responses. Int J Biochem Cell Biol. 2004;36(8):1380–1385. doi:10.1016/j.biocel.2004.01.019.
  54. Gastañaduy PA, Goodson JL, Panagiotakopoulos L, Rota PA, Orenstein WA, Patel M. Measles in the 21st century: Progress toward achieving and sustaining elimination. J Infect Dis. 2021;224(Suppl 4):S420–S428. doi:10.1093/infdis/jiaa793.
  55. Okada H, Kobune F, Sato TA, et al. Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients. Arch Virol. 2000;145(5):905–920. doi:10.1007/s007050050683.
  56. Griffin DE. Measles virus‑induced suppression of immune responses. Immunol Rev. 2010;236(1):176–189. doi:10.1111/j.1600-065x.2010.00925.x.
  57. de Vries RD, McQuaid S, van Amerongen G, et al. Measles immune suppression: Lessons from the macaque model. PLoS Pathog. 2012;8(8):e1002885. doi:10.1371/journal.ppat.1002885.
  58. Plemper, R. K., & Lamb, R. A. (2020). Paramyxoviridae: The viruses and their replication. In: P. M. Howley, D. M. Knipe, S. P. J. Whelan, & J. I. Cohen (Eds.), Fields virology: Emerging viruses (7th ed., Vol. 1, pp. 504–558). Wolters Kluwer.
  59. Mina MJ, Kula T, Leng Y, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science. 2019;366(6465):599–606. doi:10.1126/science.aay6485.
  60. Laksono BM, de Vries RD, Verburgh RJ, et al. Studies into the mechanism of measles‑associated immune suppression during a measles outbreak in the Netherlands. Nat Commun. 2018;9(1). doi:10.1038/s41467-018-07515-0.
  61. Morales GB, Muñoz MA. Immune amnesia induced by measles and its effects on concurrent epidemics. J R Soc Interface. 2021;18(179):20210153. doi:10.1098/rsif.2021.0153.
  62. Wesemann DR. Game of clones: How measles remodels the B cell landscape. Sci Immunol. 2019;4(41):eaaz4195. doi:10.1126/sciimmunol.aaz4195.
  63. Anh L, Mulholland K. Measles 2025. N Engl J Med. Published June 25, 2025. doi:10.1056/nejmra2504516.
  64. Ludlow M, Lemon K, de Vries RD, et al. Measles virus infection of epithelial cells in the macaque upper respiratory tract is mediated by subepithelial immune cells. J Virol. 2013;87(7):4033–4042. doi:10.1128/JVI.03258-12.
  65. Enwonwu CO, Falkler WA, Idigbe EO. Oro‑facial gangrene (noma/cancrum oris): Pathogenetic mechanisms. Crit Rev Oral Biol Med. 2000;11(2):159–171. doi:10.1177/10454411000110020201.
  66. Enwonwu CO, Falkler WA, Phillips RS. Noma (cancrum oris). Lancet. 2006;368(9530):147–156. doi:10.1016/s0140-6736(06)69004-1.
  67. Rytter MJH, Kolte L, Briend A, Friis H, Christensen VB. The immune system in children with malnutrition—A systematic review. PLoS One. 2014;9(8):e105017. doi:10.1371/journal.pone.0105017.
  68. Schaible UE, Kaufmann SHE. Malnutrition and infection: Complex mechanisms and global impacts. PLoS Med. 2007;4(5):e115. doi:10.1371/journal.pmed.0040115.
  69. Bryce J, Boschi‑Pinto C, Shibuya K, Black RE. WHO estimates of the causes of death in children. Lancet. 2005;365(9465):1147–1152. doi:10.1016/s0140-6736(05)71877-8.
  70. Sarker SA, Wahed MA, Rahaman MM, Alam AN, Islam A, Jahan F. Persistent protein losing enteropathy in post measles diarrhoea. Arch Dis Child. 1986;61(8):739–743. doi:10.1136/adc.61.8.739.
  71. Wahed MA, Rahaman MM, Gilman RH, Greenough WB, Sarker SA. Protein‑losing enteropathy in diarrhoea: Application of alpha 1‑antitrypsin assay. 1981.
  72. Stephensen CB, Alvarez JO, Kohatsu J, Hardmeier R, Kennedy JI, Gammon RB. Vitamin A is excreted in the urine during acute infection. Am J Clin Nutr. 1994;60(3):388–392. doi:10.1093/ajcn/60.3.388.
  73. Villamor E, Fawzi WW. Effects of vitamin A supplementation on immune responses and correlation with clinical outcomes. Clin Microbiol Rev. 2005;18(3):446–464. doi:10.1128/cmr.18.3.446-464.2005.
  74. Inua M, Duggan MB, West CE, et al. Post‑measles corneal ulceration in children in northern Nigeria: The role of vitamin A, malnutrition and measles. Ann Trop Paediatr. 1983;3(4):181–191. doi:10.1080/02724936.1983.11748292.
  75. Alexander M, Murthy JMK. Acute disseminated encephalomyelitis: Treatment guidelines. Ann Indian Acad Neurol. 2011;14(Suppl 1):S60–S64. doi:10.4103/0972-2327.83095.
  76. Pohl D, Alper G, Van Haren K, et al. Acute disseminated encephalomyelitis. Neurology. 2016;87(9 Suppl 2):S38–S45. doi:10.1212/wnl.0000000000002825.
  77. Patterson MC. Neurological complications of measles (rubeola). Curr Neurol Neurosci Rep. 2020;20(2). doi:10.1007/s11910-020-1023-y.
  78. Jabbour JT. Epidemiology of subacute sclerosing panencephalitis (SSPE). JAMA. 1972;220(7):959. doi:10.1001/jama.1972.03200070051006.
  79. Dang S. Six ways measles can affect the eyes. American Academy of Ophthalmology. Published March 5, 2015. https://www.aao.org/eye-health/tips-prevention/six-ways-measles-can-affect-eyes-2.
  80. Ivanova OH, Gaydamaka TB, Drozhzhyna GI, Veliksar TA. Characteristics of measles keratoconjunctivitis in adults. J Ophthalmol (Ukraine). 2018;1:78–80. doi:10.31288/oftalmolzh201817880.
  81. Shahid E, Fasih U, Arshad S. Ocular complications of measles: A case series. Pak J Ophthalmol. 2017;33(3).
  82. Semba RD, Bloem MW. Measles blindness. Surv Ophthalmol. 2004;49(2):243–255. doi:10.1016/j.survophthal.2003.12.005.
  83. Leal I, Sousa DC, Pinto F, Rodrigues W. An old “new” friend: Postmeasles blindness in the 21st century. BMJ Case Rep. 2015;2015:bcr2015211766. doi:10.1136/bcr-2015-211766.
  84. World Health Organization. Integrated management of childhood illness (IMCI) set of distance learning modules. Published November 18, 2014. https://www.who.int/publications/i/item/9789241506823.
DOI: https://doi.org/10.5334/aogh.5307 | Journal eISSN: 2214-9996
Language: English
Page range: 105 - 105
Submitted on: Apr 13, 2026
Accepted on: Sep 28, 2026
Published on: Oct 26, 2026
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services

© 2026 Abhijeet V. Jadhav, Sankalp Ghadei, Sanket Sonawane, Pushkar Patil, Prashant Birajdar, Avinash Deoshatwar, Kunal Pise, Amol Nath, Shailesh Pawar, Naveen Kumar, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.